scholarly journals Humoral immune responses in humanized BLT mice immunized with West Nile virus and HIV-1 envelope proteins are largely mediated via human CD5+ B cells

Immunology ◽  
2011 ◽  
Vol 134 (4) ◽  
pp. 419-433 ◽  
Author(s):  
Subhabrata Biswas ◽  
Hong Chang ◽  
Phuong T. N. Sarkis ◽  
Erol Fikrig ◽  
Quan Zhu ◽  
...  
Immunology ◽  
2012 ◽  
Vol 136 (3) ◽  
pp. 361-361 ◽  
Author(s):  
Subhabrata Biswas ◽  
Hong Chang ◽  
Phuong T. N. Sarkis ◽  
Erol Fikrig ◽  
Quan Zhu ◽  
...  

PLoS ONE ◽  
2019 ◽  
Vol 14 (6) ◽  
pp. e0218928 ◽  
Author(s):  
Kelsey Roe ◽  
Daniela Giordano ◽  
Lucy B. Young ◽  
Kevin E. Draves ◽  
Ursula Holder ◽  
...  

2019 ◽  
Author(s):  
Harald Hartweger ◽  
Andrew T. McGuire ◽  
Marcel Horning ◽  
Justin J. Taylor ◽  
Pia Dosenovic ◽  
...  

AbstractA small number of HIV-1 infected individuals develop broadly neutralizing-antibodies to the virus (bNAbs). These antibodies are protective against infection in animal models. However, they only emerge 1 - 3 years after infection, and show a number of highly unusual features including exceedingly high levels of somatic mutations. It is therefore not surprising that elicitation of protective immunity to HIV-1 has not yet been possible. Here we show that mature, primary mouse and human B cells can be editedin vitrousing CRISPR/Cas9 to express mature bNAbs from the endogenousIghlocus. Moreover, edited B cells retain the ability to participate in humoral immune responses. Immunization with cognate antigen in wild type mouse recipients of edited B cells elicits bNAb titers that neutralize HIV-1 at levels associated with protection against infection. This approach enables humoral immune responses that may be difficult to elicit by traditional immunization.One-sentence summaryB cells edited by CRISPR/Cas9 to produce antibodies participate in humoral immune reactions and secrete neutralizing serum titers of anti-HIV bNAbs.


2019 ◽  
Vol 216 (6) ◽  
pp. 1301-1310 ◽  
Author(s):  
Harald Hartweger ◽  
Andrew T. McGuire ◽  
Marcel Horning ◽  
Justin J. Taylor ◽  
Pia Dosenovic ◽  
...  

A small number of HIV-1–infected individuals develop broadly neutralizing antibodies to the virus (bNAbs). These antibodies are protective against infection in animal models. However, they only emerge 1–3 yr after infection, and show a number of highly unusual features including exceedingly high levels of somatic mutations. It is therefore not surprising that elicitation of protective immunity to HIV-1 has not yet been possible. Here we show that mature, primary mouse and human B cells can be edited in vitro using CRISPR/Cas9 to express mature bNAbs from the endogenous Igh locus. Moreover, edited B cells retain the ability to participate in humoral immune responses. Immunization with cognate antigen in wild-type mouse recipients of edited B cells elicits bNAb titers that neutralize HIV-1 at levels associated with protection against infection. This approach enables humoral immune responses that may be difficult to elicit by traditional immunization.


2011 ◽  
Vol 27 (5) ◽  
pp. 469-486 ◽  
Author(s):  
Jiri Mestecky ◽  
Peter F. Wright ◽  
Lucia Lopalco ◽  
Herman F. Staats ◽  
Pamela A. Kozlowski ◽  
...  

2014 ◽  
Vol 96 (1) ◽  
pp. 65-72 ◽  
Author(s):  
Hilke Brühl ◽  
Josef Cihak ◽  
Nicole Goebel ◽  
Yvonne Talke ◽  
Kerstin Renner ◽  
...  

2005 ◽  
Vol 79 (8) ◽  
pp. 4927-4935 ◽  
Author(s):  
B. Poon ◽  
J. T. Safrit ◽  
H. McClure ◽  
C. Kitchen ◽  
J. F. Hsu ◽  
...  

ABSTRACT The lack of success of subunit human immunodeficiency virus type 1 (HIV-1) vaccines to date suggests that multiple components or a complex virion structure may be required. We previously demonstrated retention of the major conformational epitopes of HIV-1 envelope following thermal treatment of virions. Moreover, antibody binding to some of these epitopes was significantly enhanced following thermal treatment. These included the neutralizing epitopes identified by monoclonal antibodies 1b12, 2G12, and 17b, some of which have been postulated to be partially occluded or cryptic in native virions. Based upon this finding, we hypothesized that a killed HIV vaccine could be derived to elicit protective humoral immune responses. Shedding of HIV-1 envelope has been described for some strains of HIV-1 and has been cited as one of the major impediments to developing an inactivated HIV-1 vaccine. In the present study, we demonstrate that treatment of virions with low-dose formaldehyde prior to thermal inactivation retains the association of viral envelope with virions. Moreover, mice and nonhuman primates vaccinated with formaldehyde-treated, thermally inactivated virions produce antibodies capable of neutralizing heterologous strains of HIV in peripheral blood mononuclear cell-, MAGI cell-, and U87-based infectivity assays. These data indicate that it is possible to create an immunogen by using formaldehyde-treated, thermally inactivated HIV-1 virions to induce neutralizing antibodies. These findings have broad implications for vaccine development.


Immunity ◽  
2009 ◽  
Vol 31 (2) ◽  
pp. 259-269 ◽  
Author(s):  
Dominique Gatto ◽  
Didrik Paus ◽  
Antony Basten ◽  
Charles R. Mackay ◽  
Robert Brink

Sign in / Sign up

Export Citation Format

Share Document